Combined intravenous treatment with ascorbic acid and desferrioxamine to reduce myocardial reperfusion injury in an experimental model resembling the clinical setting of primary PCI

Hellenic Journal of Cardiology

Volumn 53, Issue 3, 2012, Pages 195-204

  Chatziathanasiou, Georgios N ^a   Nikas, Dimitrios N ^a   Katsouras, Christos S ^b   Kazakos, Nikolaos D ^a   Bouba, Vasiliki ^a   Vougiouklakis, Theodoros ^a   Naka, Katerina K ^b   Michalis, Lampros K ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Antioxidants; Ascorbic acid; Desferrioxamine; Myocardial reperfusion injury

Indexed keywords

ASCORBIC ACID; DEFEROXAMINE; HYDROXYL RADICAL; IRON; SODIUM CHLORIDE; TETRAZOLIUM;

ANGIOPLASTY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE ARRHYTHMIA; INJURY SEVERITY; ISCHEMIA; MALE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION; REPERFUSION INJURY; SWINE;

ANIMALS; ANTIOXIDANTS; ARRHYTHMIAS, CARDIAC; ASCORBIC ACID; CORONARY VESSELS; DEFEROXAMINE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; INFUSIONS, INTRAVENOUS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RANDOM ALLOCATION; STROKE VOLUME; SUS SCROFA;

EID: 84865622123     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Moukarbel GV, Ayoub CM, Abchee AB. Pharmacological therapy for myocardial reperfusion injury. Curr Opin Pharmacol. 2004; 4: 147-153.
2. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res. 2004; 61: 461-470.
3. Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol. 1997; 58: 95-117.
4. Wang QD, Pernow J, Sjöquist PO, Rydén L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res. 2002; 55: 25-37.
5. Ryden L, Sjöquist PQ, Wang QD. Pharmacological tools for the limitation of myocardial reperfusion injury. Eur Heart J Supplements 2001; 3: C28-C35.
6. Hearse DJ. Ischaemia, reperfusion and cardioprotection: successes and failures in the journey from molecule to man. Eur Heart J Supplements 2001; 3: C11-C21.
7. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol. 2005; 100: 179-190.
8. Hiraishi H, Terano A, Razandi M, et al. Reactive oxygen metabolite-induced toxicity to cultured bovine endothelial cells: status of cellular iron in mediating injury. J Cell Physiol. 1994; 160: 132-134.
9. Mao GD, Thomas PD, Lopaschuk GD, Poznansky MJ. Superoxide dismutase (SOD)-catalase conjugates. Role of hydrogen peroxide and the Fenton reaction in SOD toxicity. J Biol Chem. 1993; 268: 416-420.
10. Chopra K, Singh M, Kaul N, Andrabi KI, Ganguly NK. Decrease of myocardial infarct size with desferrioxamine: possible role of oxygen free radicals in its ameliorative effect. Mol Cell Biochem. 1992; 113: 71-76.
11. Lesnefsky EJ, Repine JE, Horwitz LD. Deferoxamine pretreatment reduces canine infarct size and oxidative injury. J Pharmacol Exp Ther. 1990; 253: 1103-1109.
12. Watanabe BI, Limm W, Suehiro A, Suehiro G, Premaratne S, McNamara JJ. Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury. J Surg Res. 1993; 55: 537-542.
13. Reddy BR, Wynne J, Kloner RA, Przyklenk K. Pretreatment with the iron chelator desferrioxamine fails to provide sustained protection against myocardial ischaemia-reperfusion injury. Cardiovasc Res. 1991; 25: 711-718.
14. Dingchao H, Zhiduan Q, Liye H, Xiaodong F. The protective effects of high-dose ascorbic acid on myocardium against reperfusion injury during and after cardiopulmonary bypass. Thorac Cardiovasc Surg. 1994; 42: 276-278.
15. Klein HH, Pich S, Lindert S, Nebendahl K, Niedmann P, Kreuzer H. Combined treatment with vitamins E and C in experimental myocardial infarction in pigs. Am Heart J. 1989; 118: 667-673.
16. Rinne T, Mutschler E, Wimmer-Greinecker G, Moritz A, Olbrich HG. Vitamins C and E protect isolated cardiomyocytes against oxidative damage. Int J Cardiol. 2000; 75: 275-281.
17. Mickle DA, Li RK, Weisel RD, et al. Myocardial salvage with trolox and ascorbic acid for an acute evolving infarction. Ann Thorac Surg. 1989; 47: 553-557.
18. Bellows SD, Hale SL, Simkhovich BZ, Kay GL, Kloner RA. Do antioxidant vitamins reduce infarct size following acute myocardial ischemia/reperfusion? Cardiovasc Drugs Ther. 1995; 9: 117-123.
19. Westhuyzen J, Cochrane AD, Tesar PJ, et al. Effect of preoperative supplementation with alpha-tocopherol and ascorbic acid on myocardial injury in patients undergoing cardiac operations. J Thorac Cardiovasc Surg. 1997; 113: 942-948.
20. Gao F, Yao CL, Gao E, et al. Enhancement of glutathione cardioprotection by ascorbic acid in myocardial reperfusion injury. J Pharmacol Exp Ther. 2002; 301: 543-550.
21. Bolli R, Patel BS, Jeroudi MO, et al. Iron- mediated radical reactions upon reperfusion contribute to myocardial "stunning". Am J Physiol. 1990; 259 (6 Pt 2): H1901-1911.
22. Ferreira R, Burgos M, Miley J, et al. Effect of supplementing cardioplegic solution with deferoxamine on reperfused human myocadium. J Thorac Cadiovasc Surg 1990. 1990; 100: 708-714.
23. Williams RE, Zweier JL, Flaherty JT. Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts. Circulation. 1991; 83: 1006-1014.
24. Karwatowska-Prokopczuk E, Czarnowska E, Beresewicz A. Iron availability and free radical induced injury in the isolated ischaemic/reperfused rat heart. Cardiovasc Res. 1992; 26: 58-66.
25. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985; 312: 932-936.
26. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase 1: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-154.
27. Kloner RA, Darsee JR, DeBoer LW, Carlson N. Early pathologic detection of acute myocardial infarction. Arch Pathol Lab Med. 1981; 105: 403-406.
28. Fishbein MC, Meerbaum S, Rit J, et al. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J. 1981; 101: 593-600.
29. Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res. 1984; 54: 277-285.
30. Roberts MJ, Young IS, Trouton TG, et al. Transit release of lipid peroxides after coronary artery balloon angioplasty. Lancet. 1990; 336; 143-145.
31. Garlick PB, Davies MJ, Hearse DJ, Slater TF. Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy. Circ Res. 1987; 61: 757-760.
32. Paquin J, Aouffen M, De Grandpré E, Nadeau R, Langlois D, Mateescu MA. Neuroprotective and cardioprotective actions of an association of pyruvate, vitamin E and fatty acids. Arzneimittelforschung. 2005; 55: 359-369.
33. Karahaliou A, Katsouras C, Koulouras V, et al. Ventricular arrhythmias and antioxidative medication: experimental study. Hellenic J Cardiol. 2008; 49: 320-328.
34. Kobayashi S, Tadokoro H, Wakida Y, et al. Coronary venous retroinfusion of deferoxamine reduces infarct size in pigs. J Am Coll Cardiol. 1991; 18: 621-627.
35. Chambers DJ, Astras G, Takahashi A, Manning AS, Braimbridge MV, Hearse DJ. Free radicals and cardioplegia: organic anti-oxidants as additives to the St Thomas' Hospital cardioplegic solution. Cardiovasc Res. 1989; 23; 351-358.
36. Molyneux CA, Glyn MC, Ward BJ. Oxidative stress and cardiac microvascular structure in ischemia and reperfusion: the protective effect of antioxidant vitamins. Microvasc Res. 2002; 64: 265-277.
37. Doppelfeld IS, Parnham MJ. Experimental conditions determine effects of ascorbic acid on reperfusion injury: comparison of tissue damage with hemodynamic parameters in rat isolated hearts. Methods Find Exp Clin Pharmacol. 1992; 14: 419-430.
38. Nikas DN, Chatziathanasiou G, Kotsia A, et al. Effect of intravenous administration of antioxidants alone and in combination on myocardial reperfusion injury in an experimental pig model. Cur Ther Res. 2008; 69: 423-439.
39. Cokkinos DV, Pantos C. Myocardial protection: a new holy grail of contemporary cardiology. Hellenic J Cardiol. 2005; 46: 249-257.
40. Lecour S, Rochette L, Opie L. Free radicals trigger TNFainduced cardioprotection. Cardiovasc Res. 2005; 65: 239-243.
41. Moinuddin G, Inamdar MN, Kulkarni KS, Kulkarni C. Modulation of hemodynamics, endogenous antioxidant enzymes, and pathophysiological changes by angiotensin-converting enzyme inhibitors in pressure-overload rats. Hellenic J Cardiol. 2011; 52: 216-226.
42. Sirpal S. Cardiac signaling and the "convergent hypothesis": Probing the structural-functional nexus of the heart. Hellenic J Cardiol 2010: 49; 428-436.
43. Kumar D, Lou H, Singal PK. Oxidative stress and apoptosis in heart dysfunction. Herz. 2002; 27: 662-668.
44. Maulik N, Yoshida T. Oxidative stress developed during open heart surgery induces apoptosis: reduction of apoptotic cell death by ebselen, a glutathione peroxidase mimic. J Cardiovasc Pharmacol. 2000; 36: 601-608.
45. Vanden Hoek T, Qin Y, Wojcik K, et al. Reperfusion, not simulated ischemia, initiates intrinsic apoptosis injury in chick cardiomyocytes. Am J Physiol Heart Circ Physiol. 2003; 284: H141-150.